Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $53.5 million.

  • Puma Biotechnology's Cash & Equivalents fell 20.42% to $53.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.5 million, marking a year-over-year decrease of 20.42%. This contributed to the annual value of $69.2 million for FY2024, which is 18.17% down from last year.
  • Puma Biotechnology's Cash & Equivalents amounted to $53.5 million in Q3 2025, which was down 2.08% from $54.7 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Cash & Equivalents registered a high of $95.7 million during Q1 2021, and its lowest value of $52.8 million during Q2 2022.
  • For the 3-year period, Puma Biotechnology's Cash & Equivalents averaged around $67.2 million, with its median value being $67.1 million (2024).
  • As far as peak fluctuations go, Puma Biotechnology's Cash & Equivalents tumbled by 41.28% in 2022, and later increased by 25.01% in 2024.
  • Puma Biotechnology's Cash & Equivalents (Quarterly) stood at $63.1 million in 2021, then rose by 20.70% to $76.2 million in 2022, then increased by 11.00% to $84.6 million in 2023, then fell by 18.17% to $69.2 million in 2024, then dropped by 20.42% to $53.5 million in 2025.
  • Its Cash & Equivalents stands at $53.5 million for Q3 2025, versus $54.7 million for Q2 2025 and $63.0 million for Q1 2025.